T. Crofts

1.4k total citations
10 papers, 1.0k citations indexed

About

T. Crofts is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, T. Crofts has authored 10 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Epidemiology. Recurrent topics in T. Crofts's work include Lung Cancer Research Studies (6 papers), Cancer therapeutics and mechanisms (5 papers) and Neuroendocrine Tumor Research Advances (4 papers). T. Crofts is often cited by papers focused on Lung Cancer Research Studies (6 papers), Cancer therapeutics and mechanisms (5 papers) and Neuroendocrine Tumor Research Advances (4 papers). T. Crofts collaborates with scholars based in United Kingdom, United States and Russia. T. Crofts's co-authors include Graham Ross, G. Dane, Yaroslav Shparyk, Nicholas Thatcher, Tudor–Eliade Ciuleanu, Mary O’Brien, Gábor Juhász, Robert A. Figlin, Ian D. Davis and Lini Pandite and has published in prestigious journals such as Journal of Clinical Oncology, Lung Cancer and Journal of Clinical Gastroenterology.

In The Last Decade

T. Crofts

10 papers receiving 982 citations

Peers

T. Crofts
Ila Tamaskar United States
Mona Fouad Egypt
You‐Jian He China
Xi‐Lei Zhou China
P F Engstrom United States
Nathalie Théou–Anton France
Shin Nakahira Japan
Matteo Brighenti Italy
Yoshinori Hirashima Japan
Amer H. Zureikat United States
Ila Tamaskar United States
T. Crofts
Citations per year, relative to T. Crofts T. Crofts (= 1×) peers Ila Tamaskar

Countries citing papers authored by T. Crofts

Since Specialization
Citations

This map shows the geographic impact of T. Crofts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Crofts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Crofts more than expected).

Fields of papers citing papers by T. Crofts

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Crofts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Crofts. The network helps show where T. Crofts may publish in the future.

Co-authorship network of co-authors of T. Crofts

This figure shows the co-authorship network connecting the top 25 collaborators of T. Crofts. A scholar is included among the top collaborators of T. Crofts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Crofts. T. Crofts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Hutson, Thomas E., Ian D. Davis, Jean‐Pascal Machiels, et al.. (2009). Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 28(3). 475–480. 229 indexed citations
2.
Hutson, Thomas E., Ian D. Davis, J. H. Machiels, et al.. (2008). Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. Journal of Clinical Oncology. 26(15_suppl). 5046–5046. 67 indexed citations
3.
Hutson, Thomas E., Ian D. Davis, J-P. Machiels, et al.. (2007). Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology. 25(18_suppl). 5031–5031. 53 indexed citations
4.
O’Brien, Mary, Tudor–Eliade Ciuleanu, Yaroslav Shparyk, et al.. (2006). Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Journal of Clinical Oncology. 24(34). 5441–5447. 449 indexed citations
5.
Eckardt, John R., Joachim von Pawel, Zsolt Pápai, et al.. (2006). Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer. Journal of Clinical Oncology. 24(13). 2044–2051. 110 indexed citations
6.
7.
Ciuleanu, T-E., et al.. (2005). O-157 Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC. Lung Cancer. 49. S54–S54. 16 indexed citations
8.
9.
10.
Pandak, William M., Robert L. Jesse, T. Crofts, et al.. (2002). Short Course of Omeprazole. Journal of Clinical Gastroenterology. 35(4). 307–314. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ila Tamaskar Breakdown of academic impact, for papers by Mona Fouad Breakdown of academic impact, for papers by You‐Jian He Breakdown of academic impact, for papers by Xi‐Lei Zhou Breakdown of academic impact, for papers by P F Engstrom Breakdown of academic impact, for papers by Nathalie Théou–Anton Breakdown of academic impact, for papers by Shin Nakahira Breakdown of academic impact, for papers by Matteo Brighenti Breakdown of academic impact, for papers by Yoshinori Hirashima Breakdown of academic impact, for papers by Amer H. Zureikat
Rankless by CCL
2026